Literature DB >> 17873131

The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study.

Martin A Walter1, Christian P Turtschi, Christian Schindler, Peter Minnig, Jan Müller-Brand, Beat Müller.   

Abstract

UNLABELLED: The long-term dental safety profile of high-dose radioiodine therapy remained elusive despite more than 6 decades of clinical use.
METHODS: In a cohort study, we investigated the incidence of sialadenitis, xerostomia, caries, and tooth extractions after high-dose radioiodine therapy for differentiated thyroid cancer and explored risk factors by multiple regression models.
RESULTS: One hundred seventy-six participants were recruited (median follow-up, 6.6 y; range, 1.1-32.6 y; patient-years: 8,472 before and 1,421 after radioiodine therapy). Scintigraphic salivary gland uptake during radioiodine treatment predicted development of sialadenitis (odds ratio: 1.31 [1.05-1.63], P = 0.015) and xerostomia (odds ratio: 1.58 [1.16-2.16], P = 0.004). The caries risk increased by postradioiodine xerostomia (% increase: 98.8 [26.5-212], P = 0.003). The long-term risk for postradioiodine tooth extractions increased with increasing cumulative radioiodine activities (% increase [per gigabequerel]: 8.14 [1.07, 15.7], P = 0.02).
CONCLUSION: High-dose radioiodine treatment can impair the long-term dental health, depending on the cumulative radioiodine activity and individual salivary gland radioiodine uptake.

Entities:  

Mesh:

Year:  2007        PMID: 17873131     DOI: 10.2967/jnumed.107.042192

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

Review 1.  Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk Patients.

Authors:  E N Klein Hesselink; T P Links
Journal:  Eur Thyroid J       Date:  2015-06-11

Review 2.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 4.  Initial treatment of pediatric differentiated thyroid cancer: a review of the current risk-adaptive approach.

Authors:  Marguerite T Parisi; Hedieh Khalatbari; Sanjay R Parikh; Adina Alazraki
Journal:  Pediatr Radiol       Date:  2019-10-16

Review 5.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-17       Impact factor: 3.603

Review 6.  A systematic review of dental disease in patients undergoing cancer therapy.

Authors:  Catherine H L Hong; Joel J Napeñas; Brian D Hodgson; Monique A Stokman; Vickie Mathers-Stauffer; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-05-07       Impact factor: 3.603

7.  Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.

Authors:  R F Hobbs; W Jentzen; A Bockisch; G Sgouros
Journal:  Q J Nucl Med Mol Imaging       Date:  2013-03       Impact factor: 2.346

8.  Significance of Salivary Gland Radioiodine Retention on Post-ablation (131)I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma.

Authors:  Kyung Sook Jo; Young-Sil An; Su Jin Lee; Euy-Young Soh; Jeonghun Lee; Yoon-Sok Chung; Dae Jung Kim; Seok-Ho Yoon; Dong Hyun Lee; Joon-Kee Yoon
Journal:  Nucl Med Mol Imaging       Date:  2014-04-24

9.  Morphometric and functional changes of salivary gland dysfunction after radioactive iodine ablation in a murine model.

Authors:  Jeong-Seok Choi; In Suh Park; Seok-Ki Kim; Jae-Yol Lim; Young-Mo Kim
Journal:  Thyroid       Date:  2013-07-25       Impact factor: 6.568

Review 10.  RETRACTED ARTICLE: Radiation sialadenitis induced by high-dose radioactive iodine therapy.

Authors:  Shin Young Jeong; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2010-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.